<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="topic" /><meta name="keywords" content="Anorexia: palliative care; Prednisolone: palliative care; Dexamethasone: anorexia, palliative care; Respiratory: secretions, excessive, palliative care; Colic, bowel, palliative care; Hyoscine hydrobromide: palliative care: excessive respiratory secretions; Hyoscine hydrobromide: palliative care: bowel colic; Hyoscine butylbromide: palliative care: bowel colic; Hyoscine butylbromide: palliative care: excessive respiratory secretions; Glycopyrronium bromide: palliative care; Capillary bleeding, palliative care; Tranexamic acid: palliative care; Adrenaline: capillary bleeding, palliative care; Vitamin K: palliative care; Constipation: palliative care; Laxatives: palliative care; Methylnaltrexone: palliative care; Convulsions: palliative care; Phenytoin: convulsions, palliative care; Carbamazepine: palliative care; Diazepam: convulsions, palliative care; Phenobarbital: convulsions, palliative care; Dry mouth: palliative care; Artificial saliva: palliative care; Nystatin: mouth: palliative care; Miconazole: mouth: palliative care; Fluconazole: mouth: palliative care; Dysphagia, palliative care; Dexamethasone: dysphagia, palliative care; Dyspnoea, palliative care; Diazepam: dyspnoea, palliative care; Dexamethasone: dyspnoea, palliative care; Tumour, fungating; Metronidazole: skin: fungating tumours; Hiccup: palliative care; Antacids: palliative care; Metoclopramide: hiccup, palliative care; Baclofen: palliative care; Nifedipine: palliative care; Chlorpromazine: hiccup; Insomnia: palliative care; Benzodiazepines: hypnotics: palliative care; Cough: palliative care; Morphine: cough: palliative care; Nausea: palliative care; Vomiting: palliative care; Antiemetics: palliative care; Metoclopramide: nausea and vomiting: palliative care; Haloperidol: palliative care; Cyclizine: palliative care; Levomepromazine: palliative care; Dexamethasone: nausea and vomiting: palliative care; Pruritus: palliative care; Emollients: pruritus: palliative care; Colestyramine: pruritus: palliative care; Intracranial pressure, raised: palliative care; Dexamethasone: raised intracranial pressure, palliative care; Restlessness, palliative care; Confusion, palliative care; Haloperidol: palliative care; Levomepromazine: palliative care" /><meta name="IX" content="Anorexia: palliative care; Prednisolone: palliative care; Dexamethasone: anorexia, palliative care; Respiratory: secretions, excessive, palliative care; Colic, bowel, palliative care; Hyoscine hydrobromide: palliative care: excessive respiratory secretions; Hyoscine hydrobromide: palliative care: bowel colic; Hyoscine butylbromide: palliative care: bowel colic; Hyoscine butylbromide: palliative care: excessive respiratory secretions; Glycopyrronium bromide: palliative care; Capillary bleeding, palliative care; Tranexamic acid: palliative care; Adrenaline: capillary bleeding, palliative care; Vitamin K: palliative care; Constipation: palliative care; Laxatives: palliative care; Methylnaltrexone: palliative care; Convulsions: palliative care; Phenytoin: convulsions, palliative care; Carbamazepine: palliative care; Diazepam: convulsions, palliative care; Phenobarbital: convulsions, palliative care; Dry mouth: palliative care; Artificial saliva: palliative care; Nystatin: mouth: palliative care; Miconazole: mouth: palliative care; Fluconazole: mouth: palliative care; Dysphagia, palliative care; Dexamethasone: dysphagia, palliative care; Dyspnoea, palliative care; Diazepam: dyspnoea, palliative care; Dexamethasone: dyspnoea, palliative care; Tumour, fungating; Metronidazole: skin: fungating tumours; Hiccup: palliative care; Antacids: palliative care; Metoclopramide: hiccup, palliative care; Baclofen: palliative care; Nifedipine: palliative care; Chlorpromazine: hiccup; Insomnia: palliative care; Benzodiazepines: hypnotics: palliative care; Cough: palliative care; Morphine: cough: palliative care; Nausea: palliative care; Vomiting: palliative care; Antiemetics: palliative care; Metoclopramide: nausea and vomiting: palliative care; Haloperidol: palliative care; Cyclizine: palliative care; Levomepromazine: palliative care; Dexamethasone: nausea and vomiting: palliative care; Pruritus: palliative care; Emollients: pruritus: palliative care; Colestyramine: pruritus: palliative care; Intracranial pressure, raised: palliative care; Dexamethasone: raised intracranial pressure, palliative care; Restlessness, palliative care; Confusion, palliative care; Haloperidol: palliative care; Levomepromazine: palliative care" /><title>Miscellaneous conditions: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="29458.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="29458.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=29458.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="29403.htm">Guidance on prescribing</a> &gt; <a href="29446.htm">Prescribing in palliative care</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="29450.htm" title="Previous: Pain">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="29476.htm" title="Next: Continuous infusion devices">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_29458">Miscellaneous conditions</h1><?highlighter on?><div id="pC" class="jN"><div class="cN"><h3 class="cBP">Unlicensed indications or routes</h3><p>Several recommendations in this section involve unlicensed indications
or routes.</p></div><div id="_120052"><div class="cAZ"><h2>Anorexia</h2> <p class="cAX">Anorexia may be helped by <span>prednisolone</span> 15–30 mg daily or <span>dexamethasone</span> 2–4 mg daily.</p></div></div><div id="_29458.7"><div class="cAZ"><h2>Bowel colic and excessive respiratory secretions</h2> <p class="cAX">Bowel colic
and excessive respiratory secretions may be reduced by a subcutaneous
injection of hyoscine hydrobromide 400 micrograms, hyoscine butylbromide 20 mg, or glycopyrronium 200 micrograms. These antimuscarinics
are generally given every 4 hours when required, but hourly use is
occasionally necessary, particularly in excessive respiratory secretions.
If symptoms persist, they can be given regularly via a continuous
infusion device, see <a title="target-block: BOWEL COLIC AND EXCESSIVE RESPIRATORY SECRETIONS" href="29476.htm#_120046">Bowel Colic and Excessive
Respiratory Secretions</a>.
Care is required to avoid the discomfort of dry mouth.</p></div></div><div class="cAZ"><h2>Capillary bleeding</h2> <p class="cAX">Capillary bleeding can be treated with tranexamic acid (<a title="section: Antifibrinolytic drugs and haemostatics" href="2824.htm#_2824">section 2.11</a>) by mouth;
treatment is usually discontinued one week after the bleeding has
stopped, or, if necessary, it can be continued at a reduced dose.
Alternatively, gauze soaked in tranexamic acid 100 mg/mL or adrenaline
(epinephrine) solution 1 mg/mL (1 in 1000) can be applied to the affected
area.</p><p>Vitamin K
may be useful for the treatment and prevention of bleeding associated
with prolonged clotting in liver disease. In severe chronic cholestasis,
absorption of vitamin K may be impaired; either parenteral or water-soluble
oral vitamin K should be considered (<a title="BNF:sub-section: Vitamin K" href="5149.htm#_5149">section 9.6.6</a>).</p></div><div id="_201639"><div class="cAZ"><h2>Constipation</h2> <p class="cAX">Constipation is a common cause of distress and is
almost invariable after administration of an opioid analgesic. It
should be prevented if possible by the regular administration of laxatives; a faecal softener
with a peristaltic stimulant (e.g. co-danthramer) or <span>lactulose</span> solution with a <span>senna</span> preparation should be used
(<a title=" Stimulant laxatives" href="2206.htm#_2206">section 1.6.2</a> and <a title=" Faecal softeners" href="2230.htm#_2230">section 1.6.3</a>). Methylnaltrexone (<a title="BNF:monograph: METHYLNALTREXONE BROMIDE" href="201638.htm#_201638">section 1.6.6</a>) is
licensed for the treatment of opioid-induced constipation.</p></div></div><div class="cAZ"><h2>Convulsions</h2> <p class="cAX">Patients with cerebral tumours or uraemia may be
susceptible to convulsions. Prophylactic treatment with <span>phenytoin</span> or <span>carbamazepine</span> (<a title=" Control of epilepsy" href="3575.htm#_3575">section 4.8.1</a>) should be considered. When oral medication
is no longer possible, <span>diazepam</span> as suppositories 10–20 mg
every 4 to 8 hours, or <span>phenobarbital</span> by injection 50–200 mg
twice daily is continued as prophylaxis. For the use of <span>midazolam</span> by subcutaneous infusion using a <a title="BNF:target-block: Syringe drivers and convulsions" href="29476.htm#_201719">continuous infusion device</a>, see below.</p></div><div id="_202701"><div class="cAZ"><h2>Dry mouth</h2> <p class="cAX">Dry mouth may be relieved by good mouth care and measures such as
chewing sugar-free gum, sucking ice or pineapple chunks, or the use
of artificial
saliva (<a title=" Treatment of dry mouth" href="29680.htm#_29680">section 12.3.5</a>); dry mouth associated with candidiasis can
be treated by oral preparations of <span>nystatin</span> or <span>miconazole</span> (<a title=" Oropharyngeal anti-infective drugs" href="5701.htm#_5701">section 12.3.2</a>); alternatively, <span>fluconazole</span> can be given by mouth (<a title="BNF:sub-section: Triazole antifungals" href="208201.htm#_208201">section 5.2.1</a>). Dry mouth may be caused by
certain medications including opioids, antimuscarinic drugs (e.g.
hyoscine), antidepressants and some antiemetics; if possible, an alternative
preparation should be considered.</p></div></div><div class="cAZ"><h2>Dysphagia</h2> <p class="cAX">A corticosteroid such as <span>dexamethasone</span> 8 mg daily may help,
temporarily, if there is an obstruction due to tumour. See also <a title="BNF:target-block: Dry mouth: palliative care" href="29458.htm#_202701">Dry Mouth</a>.</p></div><div class="cAZ"><h2>Dyspnoea</h2> <p class="cAX">Breathlessness at rest may be relieved by regular oral <span>morphine</span> in carefully titrated doses, starting at 5 mg every 4 hours. <span>Diazepam</span> 5–10 mg daily may be helpful for dyspnoea associated
with anxiety. A corticosteroid, such as <span>dexamethasone</span> 4–8 mg daily, may also be helpful if there is bronchospasm or partial
obstruction.</p></div><div class="cAZ"><h2>Fungating tumours</h2> <p class="cAX">Fungating tumours can be treated by regular dressing and antibacterial
drugs; systemic treatment with <span>metronidazole</span> (<a title="BNF:monograph: METRONIDAZOLE" href="3932.htm#_3932">section 5.1.11</a>) is often required to reduce
malodour but topical <span>metronidazole</span> (<a title="BNF:monograph: METRONIDAZOLE" href="6143.htm#_6143">section 13.10.1.2</a>) is also used.</p></div><div class="cAZ"><h2>Hiccup</h2> <p class="cAX">Hiccup due to gastric distension may be helped by a preparation incorporating
an antacid with
an antiflatulent (<a title="target-text: Dimeticone for flatulence and hiccup" href="2017.htm#_2017.3">section 1.1.1</a>). If
this fails, metoclopramide 10 mg every 6 to 8 hours by mouth
or by subcutaneous or intramuscular injection can be added; if this
also fails, baclofen 5 mg twice daily, or nifedipine 10 mg three times daily, or chlorpromazine (<a title="BNF:monograph: CHLORPROMAZINE HYDROCHLORIDE" href="3210.htm#_3210">section 4.2.1</a>) can be
tried.</p></div><div class="cAZ"><h2>Hypercalcaemia</h2> <p class="cAX">see <a title="BNF:sub-sub-section: Hypercalcaemia and hypercalciuria" href="5049.htm#_5049">section 9.5.1.2</a></p></div><div class="cAZ"><h2>Insomnia</h2> <p class="cAX">Patients with advanced cancer may not sleep because of discomfort,
cramps, night sweats, joint stiffness, or fear. There should be appropriate
treatment of these problems before hypnotics are used. Benzodiazepines,
such as temazepam (<a title="BNF:sub-section: Hypnotics" href="3140.htm#_3140">section 4.1.1</a>), may be useful.</p></div><div id="_120051"><div class="cAZ"><h2>Intractable cough</h2> <p class="cAX">Intractable cough may be relieved by moist inhalations
or by regular administration of oral <span>morphine</span> in an initial
dose of 5 mg every 4 hours. Methadone linctus should be avoided because
it has a long duration of action and tends to accumulate.</p></div></div><div id="_120532"><div class="cAZ"><h2>Nausea and vomiting</h2> <p class="cAX">Nausea and vomiting are common in patients with advanced
cancer. Ideally, the cause should be determined before treatment with
an antiemetic
(<a title=" Drugs used in nausea and vertigo" href="3398.htm#_3398">section 4.6</a>) is started. A prokinetic antiemetic
may be a preferred choice for first-line therapy.</p><p>Nausea and vomiting may occur with opioid therapy particularly
in the initial stages but can be prevented by giving an antiemetic
such as <span>haloperidol</span> or metoclopramide. An antiemetic
is usually necessary only for the first 4 or 5 days and therefore
combined preparations containing an opioid with an antiemetic are
not recommended because they lead to unnecessary antiemetic therapy
(and associated side-effects when used long-term).</p><p>Metoclopramide has a prokinetic action and is used
in a dose of 10 mg 3 times daily by mouth for nausea and vomiting
associated with gastritis, gastric stasis, and functional bowel obstruction.
Drugs with antimuscarinic effects antagonise prokinetic drugs and,
if possible, should not be used concurrently.</p><p><span>Haloperidol</span> is used by mouth in an initial dose of 1.5 mg
once or twice daily (can be increased if necessary to 5–10 mg daily
in divided doses) for most metabolic causes of vomiting (e.g. hypercalcaemia,
renal failure).</p><p><span>Cyclizine</span> is given in a dose of 50 mg up to 3 times daily
by mouth. It is used for nausea and vomiting due to mechanical bowel
obstruction, raised intracranial pressure, and motion sickness.</p><p>Levomepromazine
is used as an antiemetic; it is given by mouth or by subcutaneous
injection in an initial dose of 6 mg or 6.25 mg at bedtime, titrated
if necessary to 12.5–25 mg twice daily (6-mg tablets available from <a title="BNF:appendix: Special-order Manufacturers" href="106216.htm#_106216">‘special-order’ manufacturers
or specialist importing companies</a>). For the dose by subcutaneous
infusion, see <a title="BNF:target-block: nausea vomiting palliative care" href="29476.htm#_120003">Nausea and vomiting</a>. <span>Dexamethasone</span> 8–16 mg daily by mouth can be used as an
adjunct.</p><p>Antiemetic therapy should be reviewed every 24 hours; it may
be necessary to substitute the antiemetic or to add another one.</p><p>For the administration of antiemetics by subcutaneous infusion
using a <a title="BNF:target-block: nausea vomiting palliative care" href="29476.htm#_120003">continuous infusion device</a>, see below.</p><p>For the treatment of nausea and vomiting associated with cancer
chemotherapy, see <a title=" Cytotoxic drugs" href="4676.htm#_4676">section 8.1</a>.</p></div></div><div id="_1200115"><div class="cAZ"><h2>Pruritus</h2> <p class="cAX">Pruritus, even when associated with obstructive jaundice, often responds
to simple measures such as application of emollients (<a title=" Emollients" href="5759.htm#_5759">section
13.2.1</a>). In the case of obstructive jaundice, further measures
include administration of <span>colestyramine</span> (<a title="monograph: COLESTYRAMINE" href="88939.htm#_88939">section 1.9.2</a>).</p></div></div><div id="_29458.5"><div class="cAZ"><h2>Raised intracranial pressure</h2> <p class="cAX">Headache
due to raised intracranial pressure often responds to a high dose
of a corticosteroid, such as <span>dexamethasone</span> 16 mg daily for 4 to 5 days, subsequently reduced to 4–6 mg daily
if possible; <span>dexamethasone</span> should be given before
6 p.m. to reduce the risk of insomnia.</p></div></div><div id="_29458.6"><div class="cAZ"><h2>Restlessness and confusion</h2> <p class="cAX">Restlessness and confusion may require treatment with an antipsychotic,
e.g. haloperidol 2 mg by mouth or 2.5 mg by subcutaneous
injection, or levomepromazine 6 mg by mouth or 6.25 mg by subcutaneous injection,
both repeated every 2 hours if required. The dose and frequency is
adjusted according to the level of patient distress and the response.
A regular maintenance dose should also be considered, given twice
daily either by mouth or by subcutaneous injection; alternatively
use a continuous infusion device, see <a title="target-block: RESTLESSNESS AND CONFUSION" href="29476.htm#_5.13">Restlessness and Confusion</a>.</p></div></div></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="29450.htm">Previous: Pain</a> | <a class="top" href="29458.htm#">Top</a> | <a accesskey="]" href="29476.htm">Next: Continuous infusion devices</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>